March 17, 2014 - The court preliminarily approved the settlement.
February 11, 2014 - Parties filed a stipulation of settlement.

March 22, 2013 - The court granted in part and denied in part the defendants' motion to dismiss.

September 21, 2012 - The defendants filed a motion to dismiss.

August 10, 2012 - The lead plaintiff filed a second amended complaint.

July 12, 2012 - The court granted the defendants' motion to dismiss and granted lead plaintiff leave to file an amended complaint.

July 15, 2011 - The defendants filed a motion to dismiss.

May 31, 2011 - The lead plaintiffs filed an amended consolidated complaint on behalf of investors who purchased Genoptix Inc (NASDAQ:GXDX) common shares between July 31, 2009 and June 16, 2010. The lead plaintiffs alleges that the defendants violated the Securities Act of 1934 by issuing false and misleading statements between July 31, 2009 and June 16, 2010.

April 5, 2011 - The lead plaintiff and lead counsel were appointed and all cases were consolidated.

February 4, 2011 - Lead plaintiff motions were filed.

December 6, 2010 - An investor in shares of Genoptix Inc (NASDAQ: GXDX) filed a lawsuit in the U.S. District Court for the Southern District of California against Genoptix Inc over alleged violations of Federal Securities Laws in connection with allegedly false and misleading statements made between July 31, 2009 and June 15, 2010.

According to the complaint the plaintiff alleges that Carlsbad, California based Genoptix Inc and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing between July 31, 2009 and June 15, 2010 materially false and misleading statements regarding its business and financial results. Genoptix Inc’s 12 months Total Revenue increased from $24.02 million in 2006 to $184.38 million in 2009. Its Net Income over the same time frame went from a Net Loss of $3.76 million to a Net Income of $30.63 million in 2009. Genoptix Inc reported for the first 9 months in 2010 a combined Total Revenue of $147.86 million with a combined Net Income of $15.35 million.

The plaintiff claims that while defendants continuously hyped Genoptix Inc’s approach to hematology and oncology testing and diagnostics, projecting they would easily be able to double or triple the size of Genoptix Inc’s market share in the next three to five years. The defendants failed to disclose that Genoptix Inc’s business model was not working and was causing Genoptix Inc to lose market share. Shares of Genoptix Inc (NASDAQ: GXDX) traded during 2008 and 2009 in a range of between $23 and $38. The plaintiff claims that as a result of defendants’ false statements, Genoptix Inc’s stock (NASDAQ: GXDX) traded at artificially inflated prices between July 31, 2009 and June 15, 2010, reaching a high of $38.79 per share on April 30, 2010 falling significantly in June when, Genoptix Inc issued a press release providing a first look at its second quarter 2010 performance and updating its guidance for the full-year 2010. Genoptix Inc (NASDAQ: GXDX) reduced its revenue guidance to $210 million, down from previous guidance of $235 to $240 million, and its earnings per share guidance to $1.20 per share, down from previous guidance of $1.80 to $1.85 per share. On this news, Genoptix Inc’s (NASDAQ: GXDX) stock fell another $5.69 per share to close at $17.19 per share on June 16, 2010, a one-day decline of 25% on high volume.